Another type of glycolytic inhibitor, 3-bromopyruvate (3-BP), can block the function of hexokinase and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which are involved in the glycolytic process, and ultimately induces apoptosis of cancer cells.186,187 Liposome nanoparticles have been developed for site-specific, local delivery of 3-BP, minimizing side effects such as hepatotoxicity as well as being appliable to additional aerobic glycolysis-targeting drugs.188. This evidence concerns the gene GAPDH and cancer.